Amylin/GLP-1Investigational · FDA review

CagriSema

Last updated

Amylin analog (cagrilintide) plus GLP-1 agonist (semaglutide). Once weekly.

CagriSema (investigational)·Novo Nordisk

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells cagrisema; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average weight lost in its trials

  • 2.4 mg / 2.4 mg weekly (CagriSema)REDEFINE-1 (Phase 3) · 68 wks
    −22.7% (prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) (-22.7% at 68 wks · REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema))about 45 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

Investigational: not FDA-approved for this or any use. It is still being studied in trials.

Information from FDA labels and published trials, not medical advice.

What to know about CagriSema

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−22.7% (prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) (-22.7% at 68 wks · REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema))

REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema)

A1c reduction in the cited trial
−1.9 pp (doi.org/10.1016/S2213-8587(26)00125-7) (-1.91 percentage points at 68 wks (REIMAGINE 2, type 2 diabetes, assuming adherence) · REIMAGINE 2 (Phase 3 T2D) · HbA1c change in percentage points)

REIMAGINE 2 (Phase 3 T2D)

Stopped treatment for adverse events
6% (globenewswire.com/news-release/2025/06/22/3103044/0/en/Novo-Nordisk-A-S-CagriSema-2-4-mg-2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-REDEFINE-1-published-in-New-England-Journal-of-Medicine.html) (6% vs 3.7% placebo · REDEFINE 1 (2.4/2.4 mg, obesity))

REDEFINE 1 (2.4/2.4 mg, obesity)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Once weekly

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Indications

Investigational uses

CagriSema (investigational)

Obesity; type 2 diabetes (investigational)

An investigational fixed combination of the long-acting amylin analog cagrilintide and semaglutide, pairing two complementary satiety pathways.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

CagriSema is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

6% (globenewswire.com/news-release/2025/06/22/3103044/0/en/Novo-Nordisk-A-S-CagriSema-2-4-mg-2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-REDEFINE-1-published-in-New-England-Journal-of-Medicine.html) (6% vs 3.7% placebo · REDEFINE 1 (2.4/2.4 mg, obesity))

Reported as 6% vs 3.7% placebo. The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

55% (globenewswire.com/news-release/2025/06/22/3103044/0/en/Novo-Nordisk-A-S-CagriSema-2-4-mg-2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-REDEFINE-1-published-in-New-England-Journal-of-Medicine.html) (Nausea in the drug arm · REDEFINE 1 (2.4/2.4 mg, obesity))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

GI events dominated (nausea 55%, constipation 31%, vomiting 26%), mostly transient and mild-to-moderate; despite high nausea, AE discontinuation stayed relatively low.

From REDEFINE 1 (2.4/2.4 mg, obesity). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (globenewswire.com).

Studied together

Direct trial comparisons

Read the results for the exact products, doses, and participants studied.

Evidence

Clinical trials

No indexed trial records available

Registered trials load from ClinicalTrials.gov on schedule. Search ClinicalTrials.gov (clinicaltrials.gov).

Related

Related GLP-1s to compare

Not legally for sale

FDA's warning letters naming CagriSema

5 letters to companies selling it. Nobody can legally sell CagriSema today.

  • PekCura Labs (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026)Mar 31, 2026
  • Prime Sciences (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026)Mar 31, 2026
  • Darmerica, LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025)Dec 8, 2025
  • Xcel Research LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024)Dec 10, 2024
  • Summit Research Peptides (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024)Dec 10, 2024

Every FDA warning letter on GLP-1 sellers

From PubMed

Latest CagriSema trials and reviews

  • Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial (pubmed.ncbi.nlm.nih.gov/42009015)

    Randomized trial · Lancet Diabetes Endocrinol · Apr 17, 2026 · Yamauchi T et al. · cited by 1

  • Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (pubmed.ncbi.nlm.nih.gov/40544433)

    Randomized trial · N Engl J Med · Jun 22, 2025 · Garvey WT et al. · cited by 168

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about CagriSema

How much weight can you lose on CagriSema?
In its pivotal trial (REDEFINE-1 (Phase 3)), CagriSema at 2.4 mg / 2.4 mg weekly (CagriSema) showed a mean body-weight change of -22.7% at 68 wks. This is a trial average; individual results vary. Source (prnewswire.com)
Is CagriSema available yet?
No. CagriSema is investigational (FDA review) and not FDA-approved, so it cannot be prescribed or bought yet.
When will CagriSema be FDA approved?
FDA has not approved CagriSema, and no public record gives an approval date. It is at this stage: FDA review. Source
Can you buy CagriSema?
Not legally: FDA has not approved it, so no pharmacy can fill it. FDA says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." FDA has warned companies selling unapproved GLP-1 drugs labeled for research, and says: "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." FDA's warning letters naming it: 5 from Dec 10, 2024 to Mar 31, 2026. Source (fda.gov)
How much does CagriSema cost?
It has no legal price, because it is not approved and nobody can legally sell it. Prices online are for unapproved products of unknown quality. What approved GLP-1s cost is on our price pages. Source
Does insurance cover CagriSema?
No. It is not FDA approved, so it is on no plan's list, and an HSA or FSA has nothing legal to pay for. Coverage could only come after an approval. Source
Is there a generic CagriSema?
No. It has no approved brand to copy. Anything sold as a generic of it is an unapproved product. Source
What is the CagriSema dose?
There is no approved dose, because it has no FDA label. The result we cite was at 2.4 mg / 2.4 mg weekly (CagriSema). We do not publish dosing, units or mixing charts for an unapproved medicine: those charts online describe products FDA warns against.
How does CagriSema work?
An investigational fixed combination of the long-acting amylin analog cagrilintide and semaglutide, pairing two complementary satiety pathways.
Is CagriSema a GLP-1?
Amylin analog (cagrilintide) plus GLP-1 agonist (semaglutide). Source
Who makes CagriSema?
Novo Nordisk.
Can you join a CagriSema trial?
A clinical trial is one legal way to receive a medicine FDA has not approved, but none of its registered trials is recruiting on ClinicalTrials.gov now. Source (clinicaltrials.gov)
What are the side effects of CagriSema?
GI events dominated (nausea 55%, constipation 31%, vomiting 26%), mostly transient and mild-to-moderate; despite high nausea, AE discontinuation stayed relatively low. Stopped because of side effects: 6% vs 3.7% placebo. From REDEFINE 1 (2.4/2.4 mg, obesity). These come from trials, not a label. Source (globenewswire.com)